Diagnosis and treatment response evaluation of cardiac sarcoidosis using positron emission tomography/magnetic resonance imaging

Nensa, Felix; Tezgah, Ercan; Poeppel, Thorsten D.; Naßenstein, Kai; Schlosser, Thomas

doi:10.1093/eurheartj/ehu473

Cited by 21 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…-Cardiac sarcoidosis could be a major field of application for PET/MR (100,101). Myocardial perfusion, scars, detailed morphological analysis, and functional parameters can be assessed by MR while PET depicts actively diseased myocardial areas with high sensitivity and is very well suited for assessing the course of the disease (therapy response/guidance/monitoring) (102,103). -LVV including giant cell arteritis and Takayasu arteritis.…”

Section: Pet/mr Procedurals In 4ismentioning

confidence: 99%

Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM

Slart

Glaudemans

Gheysens

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

With this document, we provide a standard for PET/(diagnostic) CT imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is). This standard should be applied in clinical practice and integrated in clinical (multicenter) trials for optimal procedural standardization. A major focus is put on procedures using [18F]FDG, but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicenter trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Finally, PET/MR applications in 4Is cardiovascular diseases are also briefly described. Diagnosis and management of 4Is-related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/MR, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications.

show abstract

Section: Pet/mr Procedurals In 4ismentioning

confidence: 99%

Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM

Slart

Glaudemans

Gheysens

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Thus, a combination of CMR and 18 F-FDG PET has the potential to provide both accurate detection as well as assessment of disease activity. Several case reports have demonstrated the feasibility of integrated 18 F-FDG PET/MRI in the detection [ 73 , 74 ] and therapy monitoring [ 76 ] of CS. One study in 51 consecutive patients with CS has found improved diagnostic accuracy of combined 18 F-FDG PET/MRI over PET and MRI alone [ 72 ].…”

Section: Inflammatory Heart Diseasementioning

confidence: 99%

Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)

et al. 2018

Self Cite

View full text Add to dashboard Cite

Positron emission tomography (PET) and magnetic resonance imaging (MRI) have both been used for decades in cardiovascular imaging. Since 2010, hybrid PET/MRI using sequential and integrated scanner platforms has been available, with hybrid cardiac PET/MR imaging protocols increasingly incorporated into clinical workflows. Given the range of complementary information provided by each method, the use of hybrid PET/MRI may be justified and beneficial in particular clinical settings for the evaluation of different disease entities. In the present joint position statement, we critically review the role and value of integrated PET/MRI in cardiovascular imaging, provide a technical overview of cardiac PET/MRI and practical advice related to the cardiac PET/MRI workflow, identify cardiovascular applications that can potentially benefit from hybrid PET/MRI, and describe the needs for future development and research. In order to encourage its wide dissemination, this article is freely accessible on the European Radiology and European Journal of Hybrid Imaging web sites.Key Points • Studies and case-reports indicate that PET/MRI is a feasible and robust technology. • Promising fields of application include a variety of cardiac conditions. • Larger studies are required to demonstrate its incremental and cost-effective value. • The translation of novel radiopharmaceuticals and MR-sequences will provide exciting new opportunities.

show abstract

“…Thus, a combination of CMR and 18 F-FDG PET has the potential to provide both accurate detection as well as assessment of disease activity. Several case reports have demonstrated the feasibility of integrated 18 F-FDG PET/MRI in the detection [73,74] and therapy monitoring [75] of CS. One study in 51 consecutive patients with CS has found improved diagnostic accuracy of combined 18 F-FDG PET/MRI over PET and MRI alone [76].…”

Section: Cardiac Sarcoidosismentioning

confidence: 99%

Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)

Nensa

Bamberg

Rischpler

et al. 2018

European J Hybrid Imaging

Self Cite

View full text Add to dashboard Cite

Positron emission tomography (PET) and magnetic resonance imaging (MRI) have both been used for decades in cardiovascular imaging. Since 2010, hybrid PET/MRI using sequential and integrated scanner platforms has been available, with hybrid cardiac PET/MR imaging protocols increasingly incorporated into clinical workflows. Given the range of complementary information provided by each method, the use of hybrid PET/MRI may be justified and beneficial in particular clinical settings for the evaluation of different disease entities. In the present joint position statement, we critically review the role and value of integrated PET/MRI in cardiovascular imaging, provide a technical overview of cardiac PET/MRI and practical advice related to the cardiac PET/MRI workflow, identify cardiovascular applications that can potentially benefit from hybrid PET/MRI, and describe the needs for future development and research. In order to encourage its wide dissemination, this article is freely accessible on the European Radiology and European Journal of Hybrid Imaging web sites. Key Points• Studies and case-reports indicate that PET/MRI is a feasible and robust technology.• Promising fields of application include a variety of cardiac conditions. • Larger studies are required to demonstrate its incremental and cost-effective value.• The translation of novel radiopharmaceuticals and MR-sequences will provide exciting new opportunities.

show abstract

Diagnosis and treatment response evaluation of cardiac sarcoidosis using positron emission tomography/magnetic resonance imaging

Cited by 21 publications

References 2 publications

Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM

Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM

Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)

Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)

Contact Info

Product

Resources

About